Commentary to ‘Novel drug candidates targeting Alzheimer’s disease: ethical challenges with identifying the relevant patient population’
The article by Gustavsson et al 1 addresses the important question how to handle new medications with focus on drug candidates that reduce Aβ or tau in the brain, for individuals with Alzheimer’s disease (AD), where the need for a disease-modifying drug is enormous.There are several ethical issues t...
| Main Author: | |
|---|---|
| Format: | Electronic Article |
| Language: | English |
| Check availability: | HBZ Gateway |
| Journals Online & Print: | Drawer...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Published: |
BMJ Publ.
2021
|
| In: |
Journal of medical ethics
Year: 2021, Volume: 47, Issue: 9, Pages: 617 |
| Online Access: |
Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
MARC
| LEADER | 00000caa a22000002 4500 | ||
|---|---|---|---|
| 001 | 1816165727 | ||
| 003 | DE-627 | ||
| 005 | 20230428063559.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220908s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/medethics-2021-107800 |2 doi | |
| 035 | |a (DE-627)1816165727 | ||
| 035 | |a (DE-599)KXP1816165727 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a Eriksdotter, Maria |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Commentary to ‘Novel drug candidates targeting Alzheimer’s disease: ethical challenges with identifying the relevant patient population’ |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The article by Gustavsson et al 1 addresses the important question how to handle new medications with focus on drug candidates that reduce Aβ or tau in the brain, for individuals with Alzheimer’s disease (AD), where the need for a disease-modifying drug is enormous.There are several ethical issues to deal with. The challenges and ethical implications associated with whom should be eligible for treatment are thoroughly discussed in the article. Should treatment only be available to those with mild symptoms and/or to those with no symptoms but with risk for AD? Where do we draw the line between who will be eligible for treatment and who will not? Who will be responsible for the prioritisation?There are many ethical problems with both population screening and screening of those with high risk well discussed in the article. Indeed, the first immunotherapy drug Aducanumab was approved by the US Food and Drug Administration (FDA)in … | ||
| 601 | |a Challenger | ||
| 601 | |a Patient | ||
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical ethics |d London : BMJ Publ., 1975 |g 47(2021), 9, Seite 617 |h Online-Ressource |w (DE-627)323607802 |w (DE-600)2026397-1 |w (DE-576)260773972 |x 1473-4257 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2021 |g number:9 |g pages:617 |
| 856 | 4 | 0 | |u https://doi.org/10.1136/medethics-2021-107800 |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://jme.bmj.com/content/47/9/617.abstract |x Verlag |z lizenzpflichtig |3 Volltext |
| 935 | |a mteo | ||
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 4185619677 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1816165727 | ||
| LOK | |0 005 20220908053806 | ||
| LOK | |0 008 220908||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2022-08-03#F2D361893C32D9ECCA8BCB4A4AC73C2386D9EEDB | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixzs |a ixrk |a zota | ||
| OAS | |a 1 |b inherited from superior work | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||